Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Status:
Terminated
Trial end date:
2021-05-20
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and
efficacy of DSTAT in patients with Acute Lung Injury (ALI) due to COVID-19. This study is
designed to determine if DSTAT can accelerate recovery and prevent progression to mechanical
ventilation in patients severely affected by COVID-19.